Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.
Thorax
; 78(11): 1138-1141, 2023 11.
Article
em En
| MEDLINE
| ID: mdl-37657926
ABSTRACT
Several clinical trials have demonstrated that anti-IL-5(R) biologics were able to improve lung function, asthma control and chronic oral corticosteroid exposure and reduce exacerbations among eosinophilic asthmatic patients. However, a certain variability in clinical responses to anti-IL-5(R) biologics was brought to light. Our study aimed at evaluating the role of baseline sputum eosinophils in identifying super-responders to mepolizumab and benralizumab. Our study reinforces the importance to examine sputum eosinophils in patients suffering from severe asthma before starting a biologic as it is associated with the intensity of response to mepolizumab and benralizumab.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Produtos Biológicos
/
Antiasmáticos
/
Eosinofilia
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article